Acrivon Therapeutics (NASDAQ:ACRV) (NASDAQ: ACRV) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for serious cardiopulmonary and rare diseases. The company’s lead asset, APD811, is a first-in-class peptide designed to activate the natriuretic peptide receptor A (NPRA) pathway and is currently being evaluated in Phase 2 studies for the treatment of pulmonary arterial hypertension (PAH). Acrivon’s research platforms leverage synthetic peptide chemistry and targeted delivery to address underlying disease biology while optimizing safety and tolerability.
In addition to its lead program, Acrivon maintains a pipeline of preclinical candidates focused on fibrotic and vascular disorders, including pulmonary fibrosis and heart failure with preserved ejection fraction (HFpEF). The company has established collaborations with leading academic centers and contract research organizations to advance its discovery efforts and conduct translational studies. By integrating in vivo pharmacology, biomarker analysis, and formulation expertise, Acrivon seeks to accelerate the development of peptide-based therapeutics that can be administered subcutaneously or via inhalation.
Founded in 2019 and headquartered in Redwood City, California, Acrivon Therapeutics emerged as a spin-out from a series of translational research programs in peptide biology. The company has since built a specialized team of drug hunters, clinical pharmacologists, and regulatory experts. Acrivon’s operations span North America and Europe, where it has established manufacturing partnerships for cGMP peptide production and engaged with patient advocacy groups to support trial enrollment in PAH and other rare disease indications.
Leadership at Acrivon is headed by Chief Executive Officer Daniel S. Lynch, Ph.D., a biotech veteran with over 20 years of experience in drug development, and President and Chief Medical Officer Dr. Isabelle Chen, whose background includes clinical development of cardiopulmonary agents. The board of directors and senior management bring collective expertise in rare disease strategy, clinical trial design, and commercialization, positioning the company to advance its pipeline toward potential registration and broader patient access.
